Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...
The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
Shares of Praxis Precision Medicines, Inc. PRAX were down 78.1% on Monday after the company announced disappointing data from the phase II/III Aria study that evaluated its pipeline candidate, ...
Earnings call Praxis reported standout topline results from the RADIANT study of vimatrogene in focal epilepsy, with a 56% median seizure reduction and 60% responder rate. Management reaffirmed POWER1 ...
Hosted on MSN
Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures
Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback